Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Feb;61(2):703-11.
doi: 10.1002/hep.27609.

Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?

Adrian M Di Bisceglie  1 , Anna S Lok, Paul Martin, Norah Terrault, Robert P Perrillo, Jay H Hoofnagle
Affiliations
Review

Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?

Adrian M Di Bisceglie et al. Hepatology. 2015 Feb.

Abstract

Reactivation of hepatitis B in the context of immunosuppressive therapy may be severe and potentially fatal. The US Food and Drug Administration has recently drawn attention to the potentially fatal risk of hepatitis B reactivation in patients receiving the anti-CD20 agents ofatumumab or rituximab. This action focuses attention on the broader issue of hepatitis B virus reactivation, which may occur with a wide variety of immunosuppressive therapies in benign or malignant disease. This article summarizes the data behind this issue. These data support the recommendation that all patients undergoing chemotherapy, immunosuppressive therapy, hematopoietic stem cell transplantation, or solid organ transplantation be screened for active or prior hepatitis B viral infection by testing for hepatitis B surface antigen and the antibody to hepatitis B core antigen in serum. Those who are found to be hepatitis B surface antigen-positive should start appropriate antiviral therapy to prevent reactivation. Additionally, even those who have recovered from hepatitis B will benefit from antiviral therapy in certain circumstances because of the risks associated with a form of hepatitis B virus reactivation referred to as "reverse seroconversion." There remain many uncertain areas that warrant further study, and further advances will benefit from close interactions between various medical specialties, regulatory agencies, and researchers.

Conclusions: There is good evidence to support routine screening of all patients for hepatitis B prior to undergoing chemotherapy or immunosuppressive treatment; use of prompt antiviral treatment appears to diminish the risk of severe or fatal reactivation of hepatitis B.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest: Dr. Di Bisceglie consults for and received grants from Gilead and Bristol-Myers Squibb; Dr. Martin consults for Gilead and Bristol-Myers Squibb; Dr. Lok consults and received grants from Gilead, advises GlaxoSmithKline, and received grants from Bristol-Myers Squibb; Dr. Perrillo advises Novartis and is on the speakers’ bureau for Gilead and Bristol-Myers Squibb; Dr. Terrault advises Bristol-Myers Squibb and received grants from Gilead.

Figures

Fig. 1
Fig. 1
Pattern of typical serological and biochemical changes associated with HBV reactivation (based on examples in Hoofnagle). Abbreviations: ALT, alanine aminotransferase.
Fig. 2
Fig. 2
Recommended algorithm for HBV testing and treatment in patients undergoing immunosuppressive therapy.
See this image and copyright information in PMC

Comment in

References

    1. US Food and Drug Administration. Boxed warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab) Drug Safety Communications. http://www.fda.-gov/downloads/Drugs/DrugSafety/UCM369436.pdf. Published September 25, 2013. Accessed October 17, 2013.
    1. Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008;57:1–20. - PubMed
    1. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, et al. Systematic review: The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148:519–528. - PMC - PubMed
    1. Yang PL, Althage A, Chung J, Maier H, Wieland S, Isogawa M, et al. Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci USA. 2010;107:798–802. - PMC - PubMed
    1. Hoofnagle JH. Reactivation of hepatitis B. HEPATOLOGY. 2009;49:S156–S165. - PubMed

Publication types

MeSH terms

Substances